CAPRICOR THERAPEUTICS INC (CAPR) Stock Overview
USA - NASDAQ:CAPR - US14070B3096 - Common Stock
CAPR Key Statistics, Chart & Performance
The current stock price of CAPR is 6.65 USD. In the past month the price decreased by -5.2%. In the past year, price increased by 31.68%.
CAPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.01 | 393.01B | ||
| AMGN | AMGEN INC | 13.09 | 153.65B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 141.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 98.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.97 | 62.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
| ARGX | ARGENX SE - ADR | 79.48 | 45.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.84 | 39.75B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.86B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 8.9 | 20.89B |
Related stock screener links
About CAPR
Company Profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 160 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Company Info
CAPRICOR THERAPEUTICS INC
10865 Road to the Cure, Suite 150
San Diego CALIFORNIA 90211 US
CEO: Linda Marban
Employees: 160
Phone: 13103583200
CAPRICOR THERAPEUTICS INC / CAPR FAQ
What is the stock price of CAPRICOR THERAPEUTICS INC today?
The current stock price of CAPR is 6.65 USD. The price increased by 3.91% in the last trading session.
What is the ticker symbol for CAPRICOR THERAPEUTICS INC stock?
The exchange symbol of CAPRICOR THERAPEUTICS INC is CAPR and it is listed on the Nasdaq exchange.
On which exchange is CAPR stock listed?
CAPR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CAPRICOR THERAPEUTICS INC stock?
16 analysts have analysed CAPR and the average price target is 21.01 USD. This implies a price increase of 215.97% is expected in the next year compared to the current price of 6.65. Check the CAPRICOR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CAPRICOR THERAPEUTICS INC worth?
CAPRICOR THERAPEUTICS INC (CAPR) has a market capitalization of 304.04M USD. This makes CAPR a Small Cap stock.
How many employees does CAPRICOR THERAPEUTICS INC have?
CAPRICOR THERAPEUTICS INC (CAPR) currently has 160 employees.
What are the support and resistance levels for CAPRICOR THERAPEUTICS INC (CAPR) stock?
CAPRICOR THERAPEUTICS INC (CAPR) has a support level at 6.42 and a resistance level at 10.69. Check the full technical report for a detailed analysis of CAPR support and resistance levels.
Is CAPRICOR THERAPEUTICS INC (CAPR) expected to grow?
The Revenue of CAPRICOR THERAPEUTICS INC (CAPR) is expected to decline by -92.12% in the next year. Check the estimates tab for more information on the CAPR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CAPRICOR THERAPEUTICS INC (CAPR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CAPR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CAPR, evaluating the profitability, health, valuation and growth aspects
- CAPRICOR THERAPEUTICS INC (CAPR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CAPRICOR THERAPEUTICS INC (CAPR) Sales and EPS estimates to see what analysts future expectations are.
- CAPRICOR THERAPEUTICS INC (CAPR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CAPRICOR THERAPEUTICS INC (CAPR) Insider and Institutional Ownership to learn about the owners and their transactions.
- CAPRICOR THERAPEUTICS INC (CAPR) Stock Chart to make your own analysis
- CAPRICOR THERAPEUTICS INC (CAPR) Latest news and press-releases to stay up to date.
Does CAPRICOR THERAPEUTICS INC (CAPR) stock pay dividends?
CAPR does not pay a dividend.
When does CAPRICOR THERAPEUTICS INC (CAPR) report earnings?
CAPRICOR THERAPEUTICS INC (CAPR) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of CAPRICOR THERAPEUTICS INC (CAPR)?
CAPRICOR THERAPEUTICS INC (CAPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.64).
What is the Short Interest ratio of CAPRICOR THERAPEUTICS INC (CAPR) stock?
The outstanding short interest for CAPRICOR THERAPEUTICS INC (CAPR) is 30.21% of its float. Check the ownership tab for more information on the CAPR short interest.
CAPR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CAPR. When comparing the yearly performance of all stocks, CAPR turns out to be only a medium performer in the overall market: it outperformed 51.87% of all stocks.
CAPR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CAPR. No worries on liquidiy or solvency for CAPR as it has an excellent financial health rating, but there are worries on the profitability.
CAPR Financial Highlights
Over the last trailing twelve months CAPR reported a non-GAAP Earnings per Share(EPS) of -1.64. The EPS decreased by -76.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.39% | ||
| ROE | -66.66% | ||
| Debt/Equity | 0 |
CAPR Forecast & Estimates
16 analysts have analysed CAPR and the average price target is 21.01 USD. This implies a price increase of 215.97% is expected in the next year compared to the current price of 6.65.
For the next year, analysts expect an EPS growth of -81.69% and a revenue growth -92.12% for CAPR